ReviewCurrent heart failure reports2026
Exercise, Nutrition and GLP-1 Medicines to Improve Body Weight and Muscle Function in Heart Failure with Preserved Ejection Fraction.
Review in Current heart failure reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purpose of reviewThis narrative review synthesizes current evidence on lifestyle, pharmacological, surgical, and multimodal interventions targeting muscle strength, body composition, and functional capacity in HFpEF with sarcopenia and/or obesity. RECENT
findingsExercise, particularly concurrent endurance and resistance training protocols, improve aerobic capacity, functional performance, symptoms, and quality of life in HFpEF. Protein supplementation may preserve muscle mass, while caloric restriction may enhance aerobic capacity and function butdecreases muscle mass. SGLT2i and GLP-1 medicines may reduce hospitalizations and improve symptoms, with GLP-1 medicines producing greater weight loss and performance benefits. Bariatric surgery may also achieve substantial weight loss and functional improvements, although evidence in HFpEF with obesity is limited. Obesity-related HFpEF may benefit from a combination of resistance exercise and adequate protein intake to preserve muscle during weight loss, while pharmacotherapy can be used to support cardiac function. Future trials should evaluate multimodal interventions to mitigate frailty risk in HFpEF.
Indexed as
Identifiers
42848257What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.